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(TIDI) [1] allows decision makers to run advanced statistical
models under different scenarios in real time, increasing trans-
parency and avoiding problems associated with preprepared
analyses. It will be particularly useful in circumstances (similar
to the examples in the article) in which there is evidence to
inform the model structure and parameters, but that evidence is
subject to uncertainty.
For some pharmaceuticals, however, there will be some parts
of an economic model where no evidence is available at all. This
is indeterminism, rather than uncertainty [2]. For example, imagine
that an adjuvant therapy has been developed for use in a
subgroup of melanoma patients (e.g., those in whom the cancer
has spread to regional nodes). Further imagine that the rando-
mized controlled trial (RCT) for marketing approval has a median
follow-up of 24 months and that the point estimate of the hazard
ratio (HR) for overall survival (OS) is 0.70 (which is considered
clinically important), but that follow-up is not long enough to
estimate median or mean OS.
For cost-utility analysis, an estimate of difference in mean
OS (i.e., life-years gained) is needed. Given the available evidence,
this will require modeling (extrapolation) of the OS beyond the
time horizon of the RCT. One option is to assume constant HRs.
This is possibly reasonable in this circumstance because, for
colon cancer, there is good evidence that the HR for OS for some
adjuvant treatments is constant (0.7) out to 8 years [3].
A competing assumption is to allow the HRs to approach 1.0
and then exceed 1.0. This is the case for some adjuvant treat-
ments for breast cancer [4], and is explainable in terms of
selection bias [5]. That is, patients with the poorest prognosis
die at different rates in the two groups, so that although the two
groups were balanced at the start of the RCT, they become
increasingly unbalanced as the RCT progresses [5].
Unless the requested price is only slightly higher than current
standard treatment (best supportive care), these two competing
assumptions (i.e., constant vs. nonconstant HR) will produce
completely divergent conclusions about the adjuvant treatment
for melanoma (i.e., cost-effective vs. dominated). From a value-
of-information perspective, the decision maker could conclude
that the long-term HR is critical information that should be
collected before a subsidy decision is made. Such information,
however, would take at least 5 years to reach maturity, during
which time there will be inequitable access to a potentially life-
prolonging drug (i.e., only those affluent enough to afford the
drug will have access).
In any case, a decision about whether to subsidize or wait for
further evidence needs to be made now, on the basis of the
currently available evidence. Given that a critical piece of evi-
dence (long-term HR for OS) is indeterminate, a full-blownial support: The author has no other financial releconomic model would not provide any more information than
a cost consequence analysis. In fact, it could be argued that the
cost consequence analysis is a clearer, more precise, and more
elegant way to help decision makers use the available (imperfect)
evidence to make a decision they cannot avoid [6].
In short, TIDI will be helpful in some circumstances, but not
all. In all jurisdictions, the resources for health care technology
assessment are finite (and in some jurisdictions they are scarce).
Therefore, judgments will be needed about when it is useful to
allocate resources to developing a full-blown economic model
with TIDI-like output and flexibility and when a simpler approach
would be as informative.
Coproduction of research for decision making is essential [7]:
prudent subsidy decisions require early and frequent interactions
between experts in clinical medicine and experts in modeling.
Often, several iterations will be required to identify the critical
inputs. This will avoid the unnecessary expense of constructing a
model with an abundance of detail in some aspects, while a
critical piece of evidence is indeterminate [8].Michael Coory, BSc, MBBS, PhD, FAFPHM
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2004;303:790–3.Transparent Interactive Decision Interrogator—Reply to Letter to the
Editor by Michael CooryTo the Editor—We thank Prof. Coory for his comments on our work
on the transparent interactive decision interrogator (TIDI). We
agree that TIDI cannot be applied to all scenarios in medical
decision making, certainly not in the form exactly presented in
our article in Value in Health [1]. This first version of TIDI was
developed as a proof-of-concept for an illustrative example in
antenatal care. Subsequently, a version of TIDI has been developed
for a real technology appraisal of biopharmaceuticals in the
treatment of psoriatic arthritis [2] to be test run within a real
reimbursement decision-making process by the National Institute
for Health and Clinical Excellence in the United Kingdom. In both
cases, the illustrative example and the real-life technology apprai-
sal, there was evidence available to populate the health-economic
model including the effectiveness data. TIDI was tailored to the
specific needs of these models. The software was, and still is,
however, at a proof-of-concept stage and it does not address all the
modeling issues. TIDI certainly does not have the ability to make
up for the lack of data; it can only facilitate the model interrogation
by using available evidence.
Despite its limitations, TIDI has a potential to be a useful tool
in exploring the boundaries of evidence. When long-term out-
comes, such as the 5-year survival rates in melanoma, are not
available, it is very difficult to make reimbursement decisions, we
agree. Systems such as TIDI, however, can enable decision
makers to carry out deterministic sensitivity analyses, for exam-
ple, of alternative extrapolation techniques to investigate the
effect of alternative assumptions on the estimates of cost-
effectiveness. Existing analogous evidence and/or background
knowledge can be built into TIDI to carry out analyses that would
help decision makers to make judgments about the relative
plausibility of different assumptions.
The version of TIDI presented in Value in Health, for the example
in antenatal care, focused mostly on the parameter uncertainty. It
can be tailored, however, to address other sources of uncertainty
such as structural uncertainty. The interrogator developed for the
psoriatic arthritis model allowed for sensitivity analyses of some
modeling assumptions, for example, alternative ways of modeling
utility and cost, alternative stopping rules for the Markov model, or
some subgroup analyses. TIDI can certainly be tailored to suit a
number of purposes and ways of dealing with uncertainty. For
example, methods of parameterizing structural uncertainty have
been developed that allow for a direct representation of the
uncertainty in the model, which can facilitate inferences about
the value of further research by estimating the expected value of
information [3]. TIDI can be adapted to facilitate this kind of
analysis. TIDI-like tools can also be designed to facilitate elicitation
of expert opinions, which can then be integrated in the model in
the form of prior distributions. Methods of elicitation of experts’
opinions have been already developed, for example, to parameter-
ize the structural uncertainty related to unknown long-termtreatment effects [4] and also to account and adjust for biases in
evidence synthesis [5]. Our future research will be focused on
designing TIDI methods for a range of commonly occurring
challenges in modeling in health technology assessment.
Prof. Coory is certainly making a valid point in saying that
discussions between experts of multidisciplinary teams are
required prior to obtaining the final model and ‘‘often several
iterations will be required to identify the critical inputs.’’ The
version of TIDI developed for the technology appraisal by the
National Institute for Health and Clinical Excellence was devel-
oped at the final stage of the modeling process when the
academic group commissioned to carry out the analysis achieved
consensus on the model structure following discussions between
clinical and statistical experts and health economists. It was
created with decision makers in mind to allow them to make
formal judgments about model assumptions, evidence, and
uncertainty. When analysts present the results to decision
makers, they are constrained to a limited number of scenarios
based on alternative modeling assumptions. TIDI facilitates the
construction of a potentially infinite number of scenarios, hence
avoiding limitations of the preprepared analysis. It can be
tailored to the needs of a specific decision problem regardless
of how small or big the problem is.
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